One of NCI's top priorities is to develop biomarkers that can preoperatively determine which among the computed tomography (CT)-found pulmonary nodules (PNs) are lung cancer. Tremendous efforts have been made to develop biomarkers by detecting cell-free (e.g., plasma) miRNAs directly released from primary lung tumors. Yet none of the biomarkers has been accepted in the clinical settings. Peripheral blood mononuclear cells (PBMCs) act as the first line of defense against malignancy in immune system, their dysfunction may occur as an early event in cancer immunogenicity or immune evasion. We have shown that the assessment of PBMC miRNAs may provide a new and immunological approach for the early detection of lung cancer. The objective of this application is to develop PBMC- based miRNA biomarkers for precisely identifying lung cancer among CT-found PNs in heavy smokers. There are two specific aims: 1), to systemically and comprehensively define PBMC miRNAs of lung cancer patients by using whole-transcriptome next-generation sequencing, and 2), to develop a panel of PBMC miRNA biomarkers for precisely identifying malignant PNs using droplet digital PCR. The success of this proposed R21-exploratory project will lead to a large and prospective study to comprehensively validate the biomarkers for lung cancer diagnosis. Future use of the biomarkers for discriminating malignant from benign PNs could spur early treatment of lung cancer, while minimizing complications from diagnostic and therapeutic procedures in smokers with benign diseases, and thus reduce lung cancer-associated deaths.

Public Health Relevance

The National Lung Screening Trial has determined that the early detection of lung cancer by computed tomography (CT) significantly reduces lung cancer-mortality. However, CT increases the number of indeterminate pulmonary nodules in asymptomatic individuals, whereas only a small fraction of pulmonary nodules are lung tumors, leading to a high level of false positive rate. The objective of the proposed project is to develop biomarkers for accurately diagnosing malignant pulmonary nodules. Future use of the biomarkers will complement CT screening for precisely diagnosing lung cancer by decreasing the false positive rate, and hence reduce lung cancer-associated deaths.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA205746-01
Application #
9101253
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Sorbara, Lynn R
Project Start
2016-04-01
Project End
2018-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Pathology
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Leng, Qixin; Lin, Yanli; Zhan, Min et al. (2018) An integromic signature for lung cancer early detection. Oncotarget 9:24684-24692
Lin, Yanli; Leng, Qixin; Jiang, Zhengran et al. (2017) A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules. Int J Cancer 141:1240-1248
Leng, Qixin; Lin, Yanli; Jiang, Fangran et al. (2017) A plasma miRNA signature for lung cancer early detection. Oncotarget 8:111902-111911
Li, Hui; Jiang, Zhengran; Leng, Qixin et al. (2017) A prediction model for distinguishing lung squamous cell carcinoma from adenocarcinoma. Oncotarget 8:50704-50714
Ma, Jie; Guarnera, Maria A; Zhou, Wenxian et al. (2017) A Prediction Model Based on Biomarkers and Clinical Characteristics for Detection of Lung Cancer in Pulmonary Nodules. Transl Oncol 10:40-45
Jiang, Feng; Todd, Nevins W; Li, Ruiyun et al. (2010) A panel of sputum-based genomic marker for early detection of lung cancer. Cancer Prev Res (Phila) 3:1571-8